Compare Merck & Co., Inc. (MRK) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sibanye Stillwater Ltd — how do they compare? Merck & Co., Inc. trades at $133.63 (market cap $321.77B), while Sibanye Stillwater Ltd trades at $10.75 (market cap $7.54B). The key difference: Merck & Co., Inc. is far larger — about 42.7× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| MRK | SBSW | |
|---|---|---|
Market Cap | $321.77B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $131.84 | $21.12 |
52-Week Low | $77.60 | $7.27 |
Enterprise Value | $368.53B | $9.19B |
Dividend Yield | 2.61% | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Sibanye Stillwater (SBSW) trades at $10.74, up 0.66% with a bullish technical signal. The company shows mixed fundamentals with a negative net income margin of -3.99% but strong operating cash flow of $10.11B in 2024. Recent earnings misses and declining revenue since 2021 highlight challenges, though analyst consensus remains positive with a $14.25 price target. Technical indicators show overbought RSI levels but strong moving average support.
SBSW presents a high-risk opportunity with significant upside potential if management executes on debt reduction and operational improvements. Key risks include persistent negative profitability, commodity price volatility, and execution challenges. The stock's deep value metrics (P/E of 4.76) contrast with operational headwinds, requiring careful monitoring of quarterly execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
